Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 212,312,112
  • Shares Outstanding, K 2,310,000
  • Annual Sales, $ 53,166 M
  • Annual Income, $ 12,611 M
  • 60-Month Beta 0.56
  • Price/Sales 4.06
  • Price/Cash Flow 11.21
  • Price/Book 4.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 1.20
  • Number of Estimates 3
  • High Estimate 1.25
  • Low Estimate 1.18
  • Prior Year 1.26
  • Growth Rate Est. (year over year) -4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
82.21 +12.48%
on 05/21/19
93.34 -0.93%
on 06/20/19
+10.46 (+12.75%)
since 05/20/19
3-Month
74.97 +23.34%
on 04/22/19
93.34 -0.93%
on 06/20/19
+10.24 (+12.46%)
since 03/20/19
52-Week
63.60 +45.40%
on 06/28/18
93.34 -0.93%
on 06/20/19
+27.18 (+41.62%)
since 06/20/18

Most Recent Stories

More News
Xealth adds Atrium Health, Cleveland Clinic and MemorialCare to close $14m Series A

Xealth, the leading platform for connecting digital health, today announced that it has secured an additional $3 million in its Series A financing, bringing the amount raised in this round to $14 million...

NVS : 92.43 (+0.57%)
The World Market for Leukemia Therapeutics 2019-2024 - Novartis is Leading the Market, Owing to Its Strong Sales Channel & Innovative Therapies

The "Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics),...

NVS : 92.43 (+0.57%)
8X8, Inc. Appoints Elizabeth Theophille to Its Board of Directors

8x8, Inc. (NYSE: EGHT), a leading cloud provider of voice, video, chat and contact center solutions for over one million users worldwide, today announced that its Board of Directors...

NVS : 92.43 (+0.57%)
EGHT : 24.59 (-0.53%)
NVS or NVO: Which Is the Better Value Stock Right Now?

NVS vs. NVO: Which Stock Is the Better Value Option?

NVO : 51.05 (-2.61%)
NVS : 92.43 (+0.57%)
NVS or NVO: Which Is the Better Value Stock Right Now?

NVS vs. NVO: Which Stock Is the Better Value Option?

NVO : 51.05 (-2.61%)
NVS : 92.43 (+0.57%)
NVS or NVO: Which Is the Better Value Stock Right Now?

NVS vs. NVO: Which Stock Is the Better Value Option?

NVO : 51.05 (-2.61%)
NVS : 92.43 (+0.57%)
NVS or NVO: Which Is the Better Value Stock Right Now?

NVS vs. NVO: Which Stock Is the Better Value Option?

NVO : 51.05 (-2.61%)
NVS : 92.43 (+0.57%)
NVS or NVO: Which Is the Better Value Stock Right Now?

NVS vs. NVO: Which Stock Is the Better Value Option?

NVO : 51.05 (-2.61%)
NVS : 92.43 (+0.57%)
NVS or NVO: Which Is the Better Value Stock Right Now?

NVS vs. NVO: Which Stock Is the Better Value Option?

NVO : 51.05 (-2.61%)
NVS : 92.43 (+0.57%)
NVS or NVO: Which Is the Better Value Stock Right Now?

NVS vs. NVO: Which Stock Is the Better Value Option?

NVO : 51.05 (-2.61%)
NVS : 92.43 (+0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade NVS with:

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 92.63
1st Resistance Point 92.27
Last Price 92.43
1st Support Level 91.26
2nd Support Level 90.61

See More

52-Week High 93.34
Last Price 92.43
Fibonacci 61.8% 81.98
Fibonacci 50% 78.47
Fibonacci 38.2% 74.96
52-Week Low 63.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar